Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

ABSTRACT:

Introduction

We present the results of a phase 2a trial of first-line avelumab (anti-programmed death-ligand 1 antibody) plus cetuximab (anti-EGFR antibody) in patients with advanced squamous NSCLC.

Methods

Patients with recurrent or metastatic squamous NSCLC received avelumab 800 mg (d 1 and 8), cetuximab 250 mg/m² (d 1) and 500 mg/m² (d 8), cisplatin 75 mg/m² (d 1), and gemcitabine 1250 mg/m² (d 1 and 8) for four 3-week cycles, followed by avelumab 800 mg and cetuximab 500 mg/m² every 2 weeks. The primary end point was the best overall response; the secondary end points were progression-free survival, duration of response, overall survival, and safety. Efficacy analyses were reported from an updated data cutoff.

Res

SUBMITTER: Andric Z 

PROVIDER: S-EPMC9883276 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature